Business Wire

KIGEN

10.8.2021 15:02:15 CEST | Business Wire | Press release

Share
AT&T and Kigen Bring SIM Flexibility to Cellular IoT Devices

AT&T and Kigen are working together to help customers streamline their supply chains and reduce the time to market for enterprises who want to leverage SIM, embedded SIM (eSIM) and integrated SIM (iSIM) secured connectivity deep in their IoT devices.

Kigen’s SIM OS, data generation and key management services will allow AT&T to offer a broader selection for integrated SIM solutions. Manufacturers will enjoy greater flexibility by sourcing their AT&T SIM at the stage of the device manufacturing process that best suits the customer. This might be at the point of contract manufacturing, module supply, or even at the chipset level by leveraging an integrated SIM and merging both chip and SIM into a single component.

Reducing complexity and accelerating time to market will attract new customers that are embarking on their cellular IoT transformation, or those that are accelerating the adoption of secure connected goods and bringing them to market sooner as a result of streamlining the chipset and SIM evaluation process.

Prior to this, device manufacturers had to purchase multiple SIM SKUs for each end-customer or market, which has complicated global product rollouts. Access to a new cache of SIMs that are compatible with cellular chipsets and secure IC vendors offers additional flexibility that results in supply chain optimisation. This streamlined approach also simplifies the manufacturing process by allowing suppliers, OEMs and licensees to identify the ideal SIM solution earlier in the design process, meaning device estates can scale sooner upon deployment.

Kigen’s SIM OS, data generation, and key management services will enable seamless access to AT&T’s Network across LTE, LTE-M, and NB-IoT technologies. Simple integration makes it easier for new entrants and established players alike to adopt cellular IoT in their devices sooner while futureproofing them with 5G readiness.

“By working with Kigen we can help enable device manufacturers to streamline their IoT device development and manufacturing.” Said William Stovall, vice president, Mobility, IoT and 5G, AT&T. “This collaboration will also offer AT&T customers the ability to bring more innovative and secure features to market sooner.”

“Scale is both cellular IoT’s most significant opportunity and hurdle. Removing the complications of placing security at the heart of IoT devices so that businesses can focus on accelerating their products is key,” said Vincent Korstanje, CEO, Kigen. “The combination of Kigen’s solutions across all types of SIM from our ecosystem with AT&T’s connectivity simplifies how businesses choose the right type of security, tuned to their manufacturing needs; offering trusted IoT that scales.”

About Kigen

At Kigen, we are making the future of securing connectivity simple. As simple as can be. As a wholly owned subsidiary of Arm, together with our partners and customers, we are unlocking new opportunities as (integrated) eSIM becomes the cornerstone of connected devices security. Our industry-leading SIM OS products enable over 2 billion SIMs. Our remote SIM provisioning and eSIM services drive this momentum further placing us amongst top 5 SIM vendors globally. Our 135 employees globally are guided by the vision of a world where every device can connect securely and reliably. For more information, go to kigen.com or speak to us on @Kigen_Ltd on Twitter and LinkedIn about #futureofSIM.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 14:29:00 CEST | Press release

Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst

IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 09:00:00 CEST | Press release

Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced d

Teijin Receives Approval for Additional Indications of XEOMIN® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 09:00:00 CEST | Press release

Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 08:00:00 CEST | Press release

Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L

Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 19:07:00 CEST | Press release

New multi-sensor system captures heart rate, movement quality, stability and muscle load to provide a more complete view of performance under fatigue Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Hel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye